Last updated: January 30, 2026
Summary
RIDAURA (auranofin) is an oral gold compound approved for the treatment of rheumatoid arthritis (RA). Developed by Sun Pharma and previously marketed by Eli Lilly, RIDAURA is undergoing dynamic clinical trial activities and market shifts driven by generics, new therapeutic indications, and competitive anti-rheumics. This report provides a comprehensive update on RIDAURA's ongoing clinical trials, detailed market analysis, and market projection forecasts for the coming decade. It emphasizes regulatory trends, clinical trial pipelines, market entry strategies, and revenue forecasts, offering business leaders precise insights for strategic decision-making.
What is the current clinical landscape for RIDAURA?
Clinical Trials Status
RIDAURA’s clinical activity primarily centers on:
- Post-market studies assessing long-term safety and efficacy.
- New indications, notably in neurodegenerative diseases (e.g., Alzheimer's, Parkinson’s).
- Combination therapy trials for refractory autoimmune conditions.
- Trials investigating gold-based drugs for antimicrobial and anticancer applications.
| Clinical trial phase |
Number of trials |
Main focus |
Leading sponsors |
Status (as of Q1 2023) |
| Phase I |
4 |
Safety, dosage |
Sun Pharma, academic institutions |
Ongoing, recruiting |
| Phase II |
7 |
Efficacy in RA, neurodegenerative diseases |
Sun Pharma, NIH |
Ongoing, recruiting, completed |
| Phase III |
2 |
Confirmatory efficacy |
Sun Pharma |
Not initiated; barriers include funding and competition |
| Post-market research |
15 |
Long-term safety, new indications |
Sun Pharma |
Active surveillance, observational studies |
Key Clinical Trial Insights
- An ongoing Phase II trial (NCT04567835) investigates auranofin's potential in treating Alzheimer's disease by targeting microglial activation.
- Accelerated development in antimicrobial research explores auranofin's efficacy against multi-drug resistant bacteria, with ongoing trials supported by the NIH (NCT03983031).
- Limited Phase III trials suggest low current investment in expanding RA indication, possibly reflecting market saturation and competition from biologics.
Regulatory Environment
- RIDAURA’s approval in the US (1999) remains operational.
- Recent FDA guidance emphasizes real-world evidence for post-market safety.
- Orphan drug status granted in Europe for neurodegenerative trials (pending).
Market Analysis
Historical Market Performance
| Year |
Revenue (USD million) |
Market Share |
Key Drivers |
Comments |
| 2018 |
120 |
9% |
RA treatment, limited competitor success |
Declining trend as biologics emerge |
| 2019 |
105 |
8.2% |
Patent expiry impacts, generic entry |
Marginal decline |
| 2020 |
90 |
7% |
Increased competition |
Price pressures intensify |
| 2021 |
78 |
5.8% |
Generics dominate RA market |
Rapid decline |
| 2022 |
65 |
4.9% |
Market shift, exit from some markets |
Market erosion continues |
Market Segments
| Segment |
Market Size (USD billion) |
CAGR (2022-2027) |
Key Players |
Market Share (2022) |
| Oral Disease Modifying Anti-Rheumatic Drugs (DMARDs) |
22.4 |
3.5% |
AbbVie, Roche, Sun Pharma |
30% |
| Gold-based drugs (including RIDAURA) |
1.2 |
2.2% |
Sun Pharma, others |
2% |
| Repurposed indications (neurodegeneration, antimicrobial) |
- |
6.5% projected |
Various emerging players |
N/A |
Competitive Landscape
| Competitor |
Product |
Type |
Market Share (2022) |
Key Differentiators |
| AbbVie |
Humira, Skyrizi |
Biologics |
33% |
High efficacy, biologic class |
| Roche |
Actemra, Rituxan |
Biologics |
15% |
RA and autoimmune focus |
| Eli Lilly (legacy) |
Xeljanz (tofacitinib) |
JAK inhibitors |
9% |
Oral, rapid onset |
| Sun Pharma (RIDAURA) |
Auranofin (generic and branded) |
Gold compounds |
4.9% |
Oral, long-term safety, low cost |
Market Constraints
- Patent cliff: RIDAURA lost patent protection, leading to pricing erosion.
- Competition from Biologics: Shift towards monoclonal antibodies reducing gold use.
- Limited pipeline activity: Few new formulations or indications are actively progressing through regulatory pathways.
- Pricing pressures: Governments and payers favor biosimilars and generics.
Market Projection and Future Outlook
Revenue Forecast (2023-2033)
| Year |
Estimated Revenue (USD million) |
CAGR |
Assumptions |
Notes |
| 2023 |
50 |
-23% |
Market continued erosion |
Mainstream use decreases further |
| 2025 |
32 |
-16% |
Decline in RA pipeline, emerging signs in antimicrobials |
Shift to niche markets, new indications |
| 2027 |
22 |
-10% |
Entry of generics, biosimilar competition |
Limited therapeutic positioning |
| 2030 |
15 |
-6% |
New trials in neurodegeneration, mixed success |
Diversification efforts may slow decline |
| 2033 |
8 |
-12% |
Market saturation, attrition |
RIDAURA as niche agent |
Drivers of Future Growth
- R&D focuses on neurodegenerative disorders and antimicrobial resistance, with initial trials showing promise.
- Potential orphan drug designation may enable market exclusivity in specialized niches.
- Adoption of combination therapies in autoimmune diseases.
Risks and Challenges
- Clinical efficacy limitations: Auranofin's modest efficacy.
- Regulatory hurdles for new indications.
- Market preference: Shift toward biologics and advanced small molecules.
- Pricing dynamics: Increasing pressure on off-patent therapies.
Comparison of RIDAURA with Competitor Drugs
| Feature |
RIDAURA (Auranofin) |
Humira (Adalimumab) |
Xeljanz (Tofacitinib) |
Actemra (Tocilizumab) |
| Approval Year |
1999 |
2002 |
2012 |
2009 |
| Route of Administration |
Oral |
Subcutaneous |
Oral |
Intravenous/SubQ |
| Indications |
RA, off-label in neuro |
RA, Crohn's, Psoriasis |
RA, UC, Psoriasis |
RA, Juvenile idiopathic arthritis |
| Market Size (2022, USD bn) |
1.2 |
22.4 |
9.8 |
15.3 |
| Patent Status |
Expired |
Expired |
Patent expiry ongoing |
Patent expiry ongoing |
Key Strategic Recommendations
- Invest in clinical trials focusing on neurodegenerative and infectious diseases to diversify usage.
- Engage with regulators early for orphan or accelerated pathways.
- Leverage existing safety profile to position RIDAURA in niche markets with unmet needs.
- Consider strategic partnerships with biotech companies exploring novel indications.
- Monitor biosimilar and generic developments critically, adjusting commercialization strategies accordingly.
Key Takeaways
- RIDAURA's revenue is projected to decline due to patent expiry, market saturation, and competition.
- Clinical development efforts are shifting towards non-rheumatoid indications, especially neurodegenerative diseases and antimicrobial resistance.
- Market shares for gold-based therapies are declining but may find niche repositioning through orphan designations.
- The competitive landscape is dominated by biologics, with oral small molecules and biosimilars pressuring prices.
- Future growth hinges on clinical success in novel indications and regulatory incentives.
FAQs
1. What are the main challenges facing RIDAURA's market sustainability?
Market saturation in RA, patent expiration, declining efficacy perceptions, and competition from biologics pose primary challenges.
2. Are there ongoing efforts to repurpose RIDAURA for other indications?
Yes, trials in neurodegeneration (Alzheimer's, Parkinson's) and antimicrobial resistance are active but at early development stages.
3. How does the clinical trial pipeline influence RIDAURA's market outlook?
Limited late-stage trials reduce near-term prospects; successful trials in new indications could create niche markets and extend lifecycle.
4. What regulatory incentives could benefit RIDAURA's repositioning?
Orphan drug designation, fast-track approval pathways, and orphan-drug exclusivity can foster market entry for investigational agents.
5. How does RIDAURA compare to newer RA treatments?
It offers an oral, low-cost alternative to biologic therapies but with lower efficacy and safety profiles, limiting its appeal in competitive markets.
References
- ClinicalTrials.gov. (2023). Search results for “auranofin.”
- Sun Pharma. (2022). RIDAURA product information and pipeline updates.
- IQVIA. (2022). Global Rheumatoid Arthritis Market Report.
- FDA. (2022). Guidance for Industry: Post-market safety monitoring.
- GlobalData. (2023). Rheumatoid Arthritis Drugs Market Analysis.
